Hertinib-40mg (Neratinib) is an advanced oral medication specifically designed to treat early-stage HER2-positive breast cancer in patients who have completed prior trastuzumab-based therapy. As a targeted therapy, Hertinib-40mg works by inhibiting the HER2 protein, which is responsible for the growth and spread of cancer cells. By blocking this protein, Hertinib-40mg helps prevent cancer from returning, offering patients improved outcomes and…
Tucaxen 150mg, with the active ingredient Tucatinib, is a cutting-edge oral medication used in Her2 positive breast cancer treatment. Designed to target and inhibit the growth of cancer cells that overexpress the HER2 protein, Tucaxen 150mg is a key player in modern cancer therapy. It is often prescribed in combination with other cancer treatments, such as trastuzumab and capecitabine, to…
